The unintended consequences of Vestager´s tougher take of „killer acquisitions“. Posted on 14.10.202129.06.2022 by Oliver Kahl
Biontech-Investoren steigen bei Alzheimerspezialisten ein Posted on 07.11.202129.06.2022 by Oliver Kahl
BioNTech´s Success Offers Antidote to EU Biopharma Skittshness Posted on 09.11.202129.06.2022 by Oliver Kahl
German Bionic debuts a new Exoskeleton with upper-and lower body assistance Posted on 13.12.202129.06.2022 by Oliver Kahl
